ReviewEULAR rheumatology open2026
Tocilizumab in German patients with RA: real-world evidence from the noninterventional studies ARATA and ICHIBAN.
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Noninterventional studies provide real-world data on treatments that complement data from randomised clinical trials. Our review article summarises evidence from the noninterventional studies rheumatoid arthritis in everyday clinical practice (ARATA) and rheumatoid arthritis (ICHIBAN), which investigated the treatment of up to 4464 German patients with active moderate-to-severe rheumatoid arthritis (RA) with the interleukin 6 receptor antagonist tocilizumab in its subcutaneous and intravenous application forms from 2010 to 2020. Subgroup analyses showed that tocilizumab was safe and effective in age, sex, and body mass index subgroups as well as in vulnerable patient populations with cardiovascular disease, renal impairment, and diabetes. Additionally, tocilizumab reduced RA-associated pain, fatigue, and sleep disturbance in these patient subgroups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.